These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 11469882)
1. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882 [TBL] [Abstract][Full Text] [Related]
2. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262 [TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF. Campora E; Pronzato P; Amoroso D; Bertelli GF; Venturini M; Baldini E; Brunetti I; Sertoli MR; Conte P; Rosso R Anticancer Res; 1992; 12(5):1555-8. PubMed ID: 1444221 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis. Oriana S; Coradini D; Sasso GM; Di Fronzo G Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717 [TBL] [Abstract][Full Text] [Related]
7. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer]. Wyss P; Rageth JC; Unger C; Hochuli E Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Bhargava V; Kell DL; van de Rijn M; Warnke RA Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038 [TBL] [Abstract][Full Text] [Related]
9. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Di Fronzo G; Coradini D; Cappelletti V; Miodini P; Granata G; Schwartz M; Panko WB Anticancer Res; 1990; 10(6):1699-705. PubMed ID: 2285244 [TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. Fisher B; Redmond C; Dimitrov NV; Bowman D; Legault-Poisson S; Wickerham DL; Wolmark N; Fisher ER; Margolese R; Sutherland C N Engl J Med; 1989 Feb; 320(8):473-8. PubMed ID: 2644531 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512 [TBL] [Abstract][Full Text] [Related]
12. Bcl-2 protein expression and long-term survival in breast cancer. Joensuu H; Pylkkänen L; Toikkanen S Am J Pathol; 1994 Nov; 145(5):1191-8. PubMed ID: 7977649 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cathepsin-D expression in female breast cancer. Aaltonen M; Lipponen P; Kosma VM; Aaltomaa S; Syrjänen K Anticancer Res; 1995; 15(3):1033-7. PubMed ID: 7645922 [TBL] [Abstract][Full Text] [Related]
14. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. Lipponen P; Pietiläinen T; Kosma VM; Aaltomaa S; Eskelinen M; Syrjänen K J Pathol; 1995 Sep; 177(1):49-55. PubMed ID: 7472779 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant cytostatic therapy of breast cancer as an important factor in the postponing of a relapse and longer survival period. Stula N Acta Med Croatica; 1992; 46(2):101-11. PubMed ID: 1384832 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Freeman JW; McGrath P; Bondada V; Selliah N; Ownby H; Maloney T; Busch RK; Busch H Cancer Res; 1991 Apr; 51(8):1973-8. PubMed ID: 1672621 [TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic significance of pathological features of breast cancer. Fisher ER NCI Monogr; 1986; (1):29-34. PubMed ID: 3774014 [TBL] [Abstract][Full Text] [Related]
18. Progesterone and estrogen receptors as prognostic variables in breast cancer. Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609 [TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096 [TBL] [Abstract][Full Text] [Related]
20. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]